Cancers · 2018 · 52 citations · 43 references
MedicineCancer BiologyPharmacologyCell SignalingSignal TransductionTumor ProgressionCancer Cell SignalingCancer ProgressionCancer-associated FibroblastsGrowth Factor SignalingOncogenic Signaling PathwaysSignal Transduction In CancerCancer Cell Proliferation InhibitionFibroblast ActivationHigh-grade Serous Ovarian CarcinomaOvarian Cancer MetastasisSerous Ovarian TumorsTransforming Growth Factor Beta Receptor SignalingTransforming Growth Factor Beta ReceptorsTransforming Growth Factor-beta Signaling
Transforming growth factor beta (TGF-β) signaling has pleiotropic functions regulating cancer initiation, development, and metastasis, and also plays important roles in the interaction between stromal and cancer cells, making the pathway a potential therapeutic target. LY2157299 monohydrate (LY), an inhibitor of TGF-β receptor I (TGFBRI), was examined for its ability to inhibit ovarian cancer (OC) growth both in high-grade serous ovarian cancer (HGSOC) cell lines and xenograft models. Immunohistochemistry, qRT-PCR, and Western blot were performed to study the effect of LY treatment on expression of cancer- and fibroblast-derived genes. Results showed that exposure to TGF-β1 induced phosphorylation of SMAD2 and SMAD3 in all tested OC cell lines, but this induction was suppressed by pretreatment with LY. LY alone inhibited the proliferation, migration, and invasion of HGSOC cells in vitro. TGF-β1-induced fibroblast activation was blocked by LY. LY also delayed tumor growth and suppressed ascites formation in vivo. In addition, independent of tumor inhibition, LY reduces ascites formation in vivo. Using OVCAR8 xenograft specimens we confirmed the inhibitory effect of LY on TGF-β signaling and tumor stromal expression of collagen type XI chain 1 (COL11A1) and versican (VCAN). These observations suggest a role for anti-TGF-β signaling-directed therapy in ovarian cancer.
43
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text
Medicine, Gynecology, Oncology +11
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +11
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke, Rileen Sinha, Douglas A. Levine et al. · Nature Communications · 2013 · 1.5K citations · Full text